The World Health Organization (WHO) has begun testing three new pharmacological drugs from Covid-19 in hospitalized patients, the organization said in a statement.
As already mentioned, these are artesunate, imatinib and infliximab, which can potentially reduce the risk of death in hospitalized patients with Covid-19. Artesunate is used in severe malaria, imatinib in some cancers and infliximab in immune system diseases such as Crohn’s disease and rheumatoid arthritis.
These drugs are provided for testing by their manufacturers.
Thousands of researchers from more than 600 hospitals in 52 countries are participating in the new phase under the auspices of the WHO Solidarity Process, which is 16 more than in the first phase of the process, BGNES reports.
This allows you to evaluate several courses of treatment at the same time, recruit thousands of patients to obtain reliable estimates of the drug’s impact on mortality and to exclude ineffective treatments.